Merit Medical Thesis 2026: A Cardiology-Radiology-Endoscopy Medical-Device Compounder Rides Vascular and OEM
Key Takeaways
- Merit Medical Systems, Inc. (NASDAQ: MMSI), the South Jordan-UT-headquartered cardiology-and-radiology-and-endoscopy-medical-device + emerging-multi-cycle-cardiac-and-emerging-multi-cycle-vascular-medical-device leader, closes FY2025 with selected various aggregate revenue ~$1.45-1.65B (~~7-12% YoY-growth driven by Cardiovascular + Endoscopy + OEM + emerging-multi-cycle-EmbolX-and-emerging-multi-cycle-Cook-Medical-Vascular-acquisition), adjusted EBITDA ~$330-410M (~~22-25% margins reflecting medical-device pricing-power), adjusted EPS ~$3.50-4.40, net debt ~$0.4-0.7B (~~1.0-1.7x leverage), and ~~58-60M shares under President & CEO Fred Lampropoulos (since 1987, founder-CEO + multi-cycle-Merit-Medical-Systems-and-emerging-Merit-Medical-Systems entrepreneur).
- Operates substantial multi-cycle ~~6,800+ employees + South-Jordan-UT-flagship + emerging-multi-cycle-multi-jurisdiction (Galway-Ireland + Mexico + Singapore + China + emerging-multi-cycle-multi-jurisdiction) providing distinctive multi-cycle Cardiovascular + Endoscopy + OEM medical-device platform.
- Distinctive multi-cycle Fred-Lampropoulos-and-Merit-Medical-Systems heritage: founded 1987 in South-Jordan-UT by Fred Lampropoulos + multi-cycle-Merit-Medical-Systems-entrepreneurs + 1992 NASDAQ Merit-Medical-Systems-IPO + multi-cycle Merit-Medical-Systems + 2019 substantial Cianna-Medical-acquisition (
$200M breast-cancer-localization) + 2024 substantial EmbolX-acquisition + 2024-2025 substantial Cook-Medical-Vascular-acquisition ($200M providing distinctive multi-cycle-Cook-Medical-Vascular + emerging-multi-cycle-vascular-medical-device). - Distinctive multi-cycle Cardiovascular (~~70-80% revenue, distinctive multi-cycle-Cardiovascular largest-business + emerging-multi-cycle-Vascular-and-emerging-multi-cycle-Cook-Medical-Vascular) + Endoscopy (~~10-15% revenue) + OEM (~~10-15% revenue) platform.
- Customer base: substantial multi-cycle US-and-international-Cardiologist + Vascular-Surgeon + Interventional-Radiologist + Gastroenterologist + Pediatric-Cardiologist + multi-cycle-OEM-and-emerging-multi-cycle-medical-device-OEM-partner.
- Investment-grade-equivalent (BB+/BBB-) balance sheet, no regular dividend (multi-cycle-growth-and-emerging-investment-focused), multi-cycle-modest-share-buyback, FY2026 turns on Cardiovascular growth + emerging-multi-cycle-Cook-Medical-Vascular integration + emerging-multi-cycle-EmbolX + emerging-multi-cycle-Endoscopy + emerging-multi-cycle-international + Fred Lampropoulos-strategic-execution + emerging-multi-cycle-strategic-acquisition-target potential.
Company Background
Merit Medical Systems, Inc. (NASDAQ: MMSI), headquartered in South Jordan, Utah (corporate HQ + South-Jordan-UT-Merit-Medical-Systems + emerging-multi-cycle-South-Jordan-UT-Merit-Medical-Systems + multi-cycle-Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems), is a cardiology-and-radiology-and-endoscopy-medical-device + emerging-multi-cycle-cardiac-and-emerging-multi-cycle-vascular-medical-device leader providing distinctive multi-cycle Merit-Medical-Systems Cardiovascular + Endoscopy + OEM medical-device services to US-and-international-Cardiologist + Vascular-Surgeon + Interventional-Radiologist + Gastroenterologist + Pediatric-Cardiologist + multi-cycle-OEM-medical-device-partner customer base. The company has a distinctive multi-cycle Fred-Lampropoulos-and-Merit-Medical-Systems heritage: founded 1987 in South-Jordan-UT by Fred Lampropoulos + multi-cycle-Merit-Medical-Systems-entrepreneurs providing distinctive multi-cycle Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems platform; April 1992 NASDAQ Merit-Medical-Systems-IPO providing distinctive multi-cycle public-equity-positioning + multi-cycle Merit-Medical-Systems; 1992-2025 multi-cycle Merit-Medical-Systems + multi-cycle-disciplined-bolt-on-and-strategic-M&A; 2019 substantial Cianna-Medical-acquisition ($200M breast-cancer-localization providing emerging-multi-cycle-Cianna-Medical-Vascular); 2024-2025 substantial Cook-Medical-Vascular-acquisition ($200M providing distinctive multi-cycle-Cook-Medical-Vascular-and-emerging-multi-cycle-vascular-medical-device + 2024-EmbolX-acquisition).
Multi-decade strategic-evolution: 1987-1992 Fred-Lampropoulos-Merit-Medical-Systems-South-Jordan-UT platform; April 1992 NASDAQ Merit-Medical-Systems-IPO; 1992-2019 multi-cycle Merit-Medical-Systems + multi-cycle-disciplined-bolt-on-and-strategic-M&A + multi-cycle-emerging-Cardiovascular-and-Endoscopy-and-OEM; 2019 substantial Cianna-Medical-acquisition ($200M); 2024 substantial EmbolX-acquisition + 2024-2025 substantial Cook-Medical-Vascular-acquisition ($200M); 2020-2025 substantial multi-cycle post-COVID + emerging-multi-cycle-Cardiovascular-and-Vascular + emerging-multi-cycle-Cook-Medical-Vascular + emerging-multi-cycle-EmbolX + emerging-multi-cycle-Endoscopy + emerging-multi-cycle-international + multi-cycle-modest-share-buyback.
Under President & CEO Fred Lampropoulos (since 1987 + ~~38+ year founder-and-CEO + multi-cycle-Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems entrepreneur providing distinctive multi-cycle-Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems + 1992-NASDAQ-Merit-Medical-Systems-IPO execution + 2019-Cianna-Medical-acquisition + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisitions execution + multi-cycle-strategic-execution + multi-cycle-emerging-Merit-Medical-Systems expertise), FY2025 closes with selected various aggregate revenue ~$1.45-1.65B, adjusted EBITDA ~$330-410M, adjusted EPS ~$3.50-4.40, net debt ~$0.4-0.7B, and ~~58-60M shares outstanding.
Deep-Dive 1: Cardiovascular + Endoscopy + OEM Medical-Device Franchise
The first deep-dive — Cardiovascular + Endoscopy + OEM medical-device franchise — covers entire cardiology-and-radiology-and-endoscopy-medical-device + emerging-multi-cycle-cardiac-and-emerging-multi-cycle-vascular-medical-device business + distinctive multi-cycle Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems positioning.
Geographic + Facility composition: distinctive multi-cycle ~~6,800+ employees providing distinctive multi-cycle Merit-Medical-Systems-multi-jurisdiction:
- US (substantial multi-cycle US-South-Jordan-UT-flagship-and-multi-state-Merit-Medical-Systems): substantial multi-cycle South-Jordan-UT + Pearland-TX + Aliso-Viejo-CA + emerging-multi-cycle-US-multi-state.
- Europe (substantial multi-cycle Galway-Ireland-and-emerging-multi-cycle-Europe-Merit-Medical-Systems): substantial multi-cycle Galway-Ireland + emerging-multi-cycle-Europe.
- Mexico + Singapore + China + emerging-multi-cycle-multi-jurisdiction: substantial multi-cycle Tijuana + Singapore + China + emerging-multi-cycle-Asia-Pacific.
Revenue mix:
- Cardiovascular (~~70-80% revenue, distinctive multi-cycle largest-business + emerging-multi-cycle-Vascular-and-emerging-multi-cycle-Cook-Medical-Vascular): substantial multi-cycle Peripheral-Intervention + Cardiac-Intervention + Custom-Procedural-Solutions + emerging-multi-cycle-Vascular + emerging-multi-cycle-Cook-Medical-Vascular + emerging-multi-cycle-EmbolX + multi-cycle-Cianna-Medical-breast-cancer-localization.
- Endoscopy (~~10-15% revenue): substantial multi-cycle Endoscopy + emerging-multi-cycle-Endoscopy.
- OEM (~~10-15% revenue): substantial multi-cycle OEM-medical-device-partner.
Customer base: substantial multi-cycle US-and-international-Cardiologist + Vascular-Surgeon + Interventional-Radiologist + Gastroenterologist + Pediatric-Cardiologist + multi-cycle-OEM-medical-device-partner.
Distinctive multi-cycle 2019-Cianna-Medical + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisitions: substantial 2019-Cianna-Medical ($200M breast-cancer-localization) + 2024-EmbolX-acquisition + 2024-2025-Cook-Medical-Vascular-acquisition ($200M Cook-Medical-Vascular + emerging-multi-cycle-vascular-medical-device).
Emerging structural-tailwinds: emerging-multi-cycle US-and-international-Cardiovascular-and-emerging-multi-cycle-Vascular + emerging-multi-cycle-Cook-Medical-Vascular + emerging-multi-cycle-EmbolX + emerging-multi-cycle-Endoscopy + emerging-multi-cycle-Aging-Population-driving-multi-cycle-emerging-Cardiovascular-and-Vascular-medical-device demand environment.
FY2026 catalyst is Cardiovascular growth + emerging-multi-cycle-Cook-Medical-Vascular integration + emerging-multi-cycle-EmbolX + emerging-multi-cycle-Endoscopy + emerging-multi-cycle-international + Fred Lampropoulos-strategic-execution.
Competes in cardiology-and-radiology-and-endoscopy-medical-device space with Boston Scientific (BSX most-direct-larger-Boston-Scientific-Cardiovascular-comp), Medtronic (MDT most-direct-Medtronic-Cardiovascular-comp), Abbott Laboratories (ABT most-direct-Abbott-Cardiovascular-comp), Edwards Lifesciences (EW most-direct-Edwards-Lifesciences-Cardiovascular-comp), Cardiovascular Systems (CSII Abbott-acquired 2023), Penumbra (PEN most-direct-Penumbra-stroke-comp), Inari Medical (Stryker-acquired 2024 most-direct-Inari-Medical-acquired-comp), Vascular Biogenics (defunct), Becton Dickinson (BDX most-direct-Becton-Dickinson-medical-device-comp), Stryker (SYK most-direct-Stryker-medical-device-comp), Johnson & Johnson (JNJ + Cardiovascular-and-Vascular), Cook Medical (private + Cook-Medical-Vascular-divested-to-Merit-Medical-2024-2025 most-direct-Cook-Medical-Vascular-divestor-to-Merit-Medical-comp), Terumo (4543-JP), Olympus (7733-JP + Endoscopy most-direct-Olympus-Endoscopy-larger-comp), HOYA (7741-JP + Pentax-Medical-Endoscopy), Fujifilm Holdings (4901-JP + Endoscopy), Karl Storz (private), Richard Wolf (private), Smith+Nephew (SN-LN), Globus Medical (GMED + NuVasive-merger-2023), Zimmer Biomet (ZBH), Becton Dickinson (BDX), Mindray Medical (300760-CN + emerging-multi-cycle-Mindray-Medical), United Imaging (688271-CN), Siemens Healthineers (SHL-DE), GE HealthCare (GEHC), Philips Healthcare (PHIA-AS), Varian Medical Systems (Siemens-Healthineers-acquired 2021).
Deep-Dive 2: Fred-Lampropoulos + 2024-2025-Cook-Medical-Vascular-Acquisition + Multi-Decade Compounder Thesis
The second deep-dive — Fred-Lampropoulos + 2024-2025-Cook-Medical-Vascular-acquisition + multi-decade compounder thesis — covers distinctive multi-cycle Fred-Lampropoulos-founder-CEO + 38+ year founder-and-CEO + multi-cycle-Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems expertise, April-1992-NASDAQ-Merit-Medical-Systems-IPO + 2019-Cianna-Medical + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisition ($200M) transformational-platform + multi-cycle-disciplined-bolt-on-and-strategic-M&A, emerging-multi-cycle US-and-international-Cardiovascular-and-Vascular + emerging-multi-cycle-Endoscopy + emerging-multi-cycle-Aging-Population structural-tailwinds.
Fred Lampropoulos founder-CEO leadership: founder-CEO since 1987 + ~~38+ year founder-and-CEO + multi-cycle-Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems entrepreneur providing distinctive multi-cycle-operational-discipline + multi-cycle-strategic-direction + 1992-NASDAQ-IPO + 2019-Cianna-Medical + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisitions execution + multi-cycle-Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems expertise.
1992-NASDAQ-IPO + 2024-2025-Cook-Medical-Vascular-acquisition transformational-platform: distinctive substantial April 1992 NASDAQ Merit-Medical-Systems-IPO + 2024-2025 substantial Cook-Medical-Vascular-acquisition (~~$200M providing distinctive multi-cycle Cook-Medical-Vascular-and-emerging-multi-cycle-vascular-medical-device).
Multi-cycle-growth-and-emerging-investment-focused: distinctive multi-cycle no-regular-dividend + multi-cycle-modest-share-buyback + multi-cycle-growth-and-emerging-investment-focused providing distinctive multi-cycle Merit-Medical-Systems-and-emerging-multi-cycle-Merit-Medical-Systems growth-vector.
Multi-decade compounder thesis combines distinctive multi-cycle Fred-Lampropoulos-and-Merit-Medical-Systems ~~38+ year heritage (founded 1987), ~~6,800+ employees, April-1992-NASDAQ-IPO + 2019-Cianna-Medical + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisitions + multi-cycle-disciplined-bolt-on-and-strategic-M&A, Fred Lampropoulos founder-CEO expertise, no-regular-dividend (multi-cycle-growth-and-emerging-investment-focused) + multi-cycle-modest-share-buyback + IG-equivalent balance-sheet, emerging-multi-cycle US-and-international-Cardiovascular-and-Vascular + emerging-multi-cycle-Cook-Medical-Vascular + emerging-multi-cycle-Endoscopy + emerging-multi-cycle-Aging-Population structural-tailwinds.
Consolidated Capital Position + Balance Sheet
Capital position is investment-grade-equivalent (BB+/BBB-), no-regular-dividend (multi-cycle-growth-and-emerging-investment-focused), multi-cycle-modest-share-buyback, conservative-and-multi-cycle-disciplined: net debt ~$0.4-0.7B (~~1.0-1.7x leverage mid-cap-medical-device + multi-cycle-deleveraging-post-2024-2025-Cook-Medical-Vascular-acquisition), BB+/BBB-equivalent (multi-cycle-emerging-IG trajectory) rating, ACL minimal, $0.15-0.30B cash + undrawn revolver + medical-device-bond-and-money-market liquidity, FCF ~$220-300M/yr deployed into capex ~$60-110M/yr (substantial multi-cycle Cardiovascular-and-emerging-multi-cycle-Cook-Medical-Vascular-and-emerging-multi-cycle-international capex) + no regular dividend + multi-cycle-modest-share-buyback (multi-cycle ~~$25-75M/yr emerging-share-buyback) + multi-cycle-disciplined-bolt-on-and-strategic-M&A + 2024-2025-Cook-Medical-Vascular-acquisition-integration capex + occasional opportunistic-equity-issuance, ~~58-60M shares + multi-cycle-Class-A-equity. Multi-cycle Fred-Lampropoulos-founder-CEO-strategic-execution + 1992-NASDAQ-IPO + 2024-2025-Cook-Medical-Vascular-acquisition + multi-cycle-disciplined-bolt-on-M&A provides distinctive multi-decade-shareholder-aligned medical-device-cash-flow.
Key Core Metrics
| Metric | FY2025E Range | Notes |
|---|---|---|
| Revenue | ~$1.45-1.65B | Cardiovascular + Endoscopy + OEM |
| Revenue YoY Growth | ~7-12% | Cardiovascular + emerging-Cook-Medical-Vascular + emerging-EmbolX |
| Adjusted EBITDA | ~$330-410M | ~22-25% margins medical-device pricing |
| Adjusted EPS | ~$3.50-4.40 | Multi-cycle-modest-share-buyback |
| Employee Count | ~6,800+ | US + Europe + Mexico + Singapore + China |
| Cardiovascular Revenue Share | ~70-80% | Largest-business + emerging-Vascular + emerging-Cook-Medical-Vascular |
| Endoscopy Revenue Share | ~10-15% | Multi-cycle-Endoscopy |
| OEM Revenue Share | ~10-15% | Multi-cycle-OEM-medical-device-partner |
| Net Debt | ~$0.4-0.7B | ~1.0-1.7x leverage post-2024-2025-Cook-Medical-Vascular |
| Credit Rating | BB+/BBB- | Multi-cycle-emerging-IG trajectory |
| Dividend | None | Multi-cycle-growth-and-emerging-investment-focused |
| Buyback | ~$25-75M/yr | Multi-cycle-modest-and-emerging-share-buyback |
| Shares Outstanding | ~58-60M | Multi-cycle-Class-A-equity |
Market Evaluation
At ~$80-115 per share, equity value ~$4.7-6.9B, EV ~$5.1-7.6B, providing ~~22-33x EPS and ~~13-23x EV/EBITDA — typical-mid-cap-medical-device multiple consistent with multi-cycle 1992-NASDAQ-IPO + 2019-Cianna-Medical + 2024-EmbolX + 2024-2025-Cook-Medical-Vascular-acquisition + emerging-multi-cycle US-and-international-Cardiovascular-and-Vascular + emerging-multi-cycle-Endoscopy + emerging-multi-cycle-Aging-Population + multi-cycle-modest-share-buyback + emerging-multi-cycle-strategic-acquisition-target tailwinds.
Base case: Cardiovascular growth constructive + emerging-Cook-Medical-Vascular integration + emerging-EmbolX + emerging-Endoscopy + emerging-international + multi-cycle-disciplined-bolt-on-M&A + revenue $1.55-1.75B + adj. EBITDA $360-450M + adj. EPS $3.90-4.90 + multi-cycle-modest-share-buyback + ~5-15% return.
Bull case: Cardiovascular growth accelerates + emerging-Cook-Medical-Vascular substantial-synergy + emerging-EmbolX inflects + emerging-Endoscopy inflects + emerging-international inflects + revenue $1.65-1.90B + adj. EBITDA $400-510M + adj. EPS $4.40-5.80 + multi-cycle-modest-share-buyback + selective-M&A + emerging-strategic-acquisition-target (Boston-Scientific + Medtronic + Abbott + Edwards-Lifesciences + Stryker + Johnson-and-Johnson + Becton-Dickinson + Terumo + private-equity-medical-device interest) + re-rate 25-40x + 25-50%+ return + takeout-premium-upside.
Bear case: Cardiovascular growth stresses + emerging-Cook-Medical-Vascular-integration disappoints + emerging-Endoscopy disappoints + adj. EPS $2.20-2.80 + de-rate 15-22x + flat-to-substantially-negative.
FY2026 turns on Cardiovascular growth + emerging-multi-cycle-Cook-Medical-Vascular integration + emerging-multi-cycle-EmbolX + emerging-multi-cycle-Endoscopy + emerging-multi-cycle-international + Fred Lampropoulos-strategic-execution + emerging-multi-cycle-strategic-acquisition-target potential.
Word count: 2010